StockData

AbCellera Biologics vs OmniAb

ABCL and OABI side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABCL and OABI compare

AbCellera Biologics is the larger company, worth 4.6 times as much as OmniAb ($3.4B against $737M).

AbCellera Biologics grew revenue faster over the last twelve months (101% versus 90.6% for OmniAb).

OmniAb keeps more of each dollar of sales as profit, with a net margin of −108% compared with −249% at AbCellera Biologics.

OmniAb scores higher on the StockData Score (9 against 8 for AbCellera Biologics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABCLOABI
Size and price
Market cap$3.4B$737M
Share price$11.03$5.05
Change, 1 year199%224%
Change, 5 years−21.2%−49.5%
Beta (5Y)2.111.68
Employees562107
StockData Score
Total score89 (better)
Valuation score01 (better)
Growth score11
Performance score11
Health score66
Dividend score00
Valuation
P/S51.1×18.3× (better)
P/B3.8×3.0× (better)
P/FCF–309×
FCF yield−3.5%0.32% (better)
Fair value$4.06$3.71
Margin of safety−172%−36.2% (better)
Growth
Revenue growth (TTM)101% (better)90.6%
Revenue growth, 5Y average−20.3%–
Profitability
Operating margin−340%−116% (better)
Net margin−249%−108% (better)
FCF margin−181%5.9% (better)
Return on equity−17.3%−16.5% (better)
Return on invested capital−43.9%−18.3% (better)
Financial health
Debt / equity0.000.00
Current ratio12.77 (better)4.21
Altman Z-score4.859.48 (better)
Piotroski F-score5 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions37.9%42.4%
Held by insiders22.8%5.9%
Insider net buying, 12 months$3.3M (better)−$283K
Short interest, % of float12.3%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.